Chat with us, powered by LiveChat

Anti-malarial Drugs Market (Drug Class - Quinine, Chloroquine, Proguanil, Mefloquine, and Others; Route of Administration - Oral, and Injectable; Distribution Channel - Hospital Pharmacy, Retail Pharmacy, E-commerce, and Others): Global Industry Analysis, Trends, Size, Share and Forecasts to 2030

Anti-malarial Drugs Market (Drug Class - Quinine, Chloroquine, Proguanil, Mefloquine, and Others; Route of Administration - Oral, and Injectable; Distribution Channel - Hospital Pharmacy, Retail Pharmacy, E-commerce, and Others): Global Industry Analysis, Trends, Size, Share and Forecasts to 2030

Report Code: IGR0278 Category: Healthcare & Medical Devices Published: December, 2023

A recent report published by Infinium Global Research on anti-malarial drugs market provides in-depth analysis of segments and sub-segments in the global as well as regional anti-malarial drugs market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional anti-malarial drugs market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global anti-malarial drugs market.

Market Insight:

The global anti-malarial drugs market was valued at USD 947.67 million in 2022 and is expected to reach USD 1360.18 million in 2030, with a CAGR of 4.70% during the forecast period 2023-2030.

Anti-malarial medicines are a type of treatment used to prevent and cure malaria, a deadly mosquito-borne infectious illness triggered by the Plasmodium parasite. These medications function by targeting several phases of the parasite's life cycle, reducing growth and reducing illness development in the human body. Malaria is a major worldwide health hazard, especially in tropical and subtropical areas, affecting hundreds of thousands of lives each year. Anti-malarial medications are also used in the fields of disease control and public health. These drugs are essential for initiatives aimed at preventing malaria since they lessen the parasite's ability to spread. Anti-malarial medication may be widely distributed in endemic regions, especially to susceptible groups such as children and pregnant women, to drastically lower the disease's occurrence. Furthermore, these medications are necessary for both residents of malaria-endemic areas and visitors to those locations. As a result of its widespread usage as a preventive measure, malaria is finally controlled and eradicated globally, saving lives and lessening the strain on medical facilities in impacted areas.

The substantial demand for anti-malarial medications is fueled by the high frequency of malaria in endemic areas. These drugs are essential for the treatment and prevention of malaria, for lessening the disease's negative effects on public health, and for saving lives in regions where malaria poses a serious risk. Additionally, the market for anti-malarial drugs is driven by the growing worldwide awareness of malaria's lethal implications. The demand for these drugs is rising as more people realize how urgent it is to stop malaria, which is accelerating research, financing, and accessibility to lessen the disease's terrible effects on public health globally. However, the high price of anti-malarial medications puts up financial obstacles, preventing many people from accessing treatment and impeding the anti-malarial market's expansion. This affordability problem limits the efficacy and reach of malaria control and preventive initiatives, which presents a serious challenge in the fight against the disease. However, new developments in medication research, such as inventive treatment strategies and unique chemicals, have the potential to completely transform anti-malarial therapy approaches. Because these novel therapies address a key global health need and offer enhanced effectiveness, fewer resistance risks, and better patient outcomes, they present a very profitable opportunity in the market.

Anti-malarial Drugs Market Size, Share, Trends, Industry | IGR

The Middle East and Africa (MEA) region holds the largest market share since malaria is quite common in several African nations. The main causes of this are government initiatives. For example, the government of the United Arab Emirates (UAE) has started a nationwide malaria prevention program that involves spraying pesticides and distributing ITNs. Additionally, to fight the illness, international organizations like the World Health Organization (WHO) have given the Jordanian government technical aid to help it create a nationwide malaria control program. However, it's imperative to stress that the MEA area has the greatest malaria load. Moreover, the Asia-Pacific (APAC) region is projected to grow at the fastest growth in the anti-malarial drug market due to its increasing population, this increases the overall demand for anti-malarial drugs. Additionally, when more individuals move into cities, they run the risk of coming into touch with the Anopheles mosquito, which spreads malaria. This may cause the number of cases of malaria in cities to rise. Moreover, modernizing existing facilities and constructing new medical centers and hospitals are all part of the process of growing the healthcare infrastructure. This increase was facilitated by the acceptance of novel treatment options and an increasing emphasis on prevention measures.

Report Scope of the Anti-malarial Drugs Market:

Report Coverage Details
Market Size in 2022 USD 947.67 Million
Market Size by 2030 USD 1360.18 Million
Growth Rate from 2023 to 2030 CAGR of 4.70%
Largest Market Middle East and Africa (MEA)
No. of Pages 255
Market Drivers
  • The high prevalence of malaria in endemic regions drives demand for anti-malarial drugs.

  • Increasing global awareness of the deadly impact of malaria drives the anti-malarial drug market.

Market Segmentation By Drug Class, By Route of Administration, and By Distribution Channel
Regional Scope North America, Europe, Asia Pacific, and RoW

Segment Covered

The report on global anti-malarial drugs market covers segments such as drug class, route of administration, and distribution channel. On the basis of drug class, the sub-markets include quinine, chloroquine, proguanil, mefloquine, and others. On the basis of route of administration, the sub-markets include oral, and injectable. On the basis of distribution channel, the sub-markets include hospital pharmacy, retail pharmacy, e-commerce, and others.

The key players involved in the market such as Pfizer Inc., weefselpharma.com, Sun Pharmaceutical Industries Ltd., Alvizia Health Care, Actiza Pharmaceutical Private Limited, Novartis AG, GSK plc., Bayer AG, Ipca Laboratories Ltd., and Merck & Co., Inc..

Report Highlights:

The report provides deep insights into demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the anti-malarial drugs market. Moreover, the study highlights current market trends and provides forecasts from 2023-2030. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.


Frequently Asked Questions (FAQ's)

The global anti-malarial drugs market was valued at USD 947.67 Million in 2022.
It is likely to grow at a CAGR of 4.70% during the forecast period 2023-2030.
The global anti-malarial drugs market is estimated to reach USD 1360.18 Million by the end of 2030.
Middle East and Africa (MEA) is anticipated to exhibit high demand for anti-malarial drugs market during the forecast period.
Pfizer Inc., weefselpharma.com., Sun Pharmaceutical Industries Ltd. , Alvizia Health Care, Actiza Pharmaceutical Private Limited, Novartis AG, GSK plc., Bayer AG, Ipca Laboratories Ltd., and Merck & Co., Inc..
CHOOSE LICENCE TYPE

Please Choose One of them.

Google translate
© 2024. Infinium Global Research LLP. All Rights Reserved.